Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-oral-dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AF76432 in Healthy Young Men
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2019
At a glance
- Drugs Lu AF76432 (Primary)
- Indications Alzheimer's disease; Cognition disorders; Schizophrenia
- Focus Adverse reactions
- Sponsors Lundbeck A/S
- 25 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
- 25 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.
- 24 May 2018 New trial record